On October 30, Encompass Health Corporation rose 6.46% in Regular Trading, trading at $130.215 per share, with turnover of $134 million.
The move followed the company’s latest quarterly results, which exceeded Wall Street expectations, alongside an increase in full-year guidance and a higher analyst price target.
For the third quarter, adjusted EPS was $1.52 versus the $1.36 consensus and $1.23 a year earlier, while revenue rose to $1.609 billion from $1.48 billion, slightly above the $1.601 billion expectation. The company lifted full-year adjusted EPS guidance to $6.23-$6.37 from $6.02-$6.25 and projected revenue of $6.45 billion-$6.50 billion, compared with prior guidance of $6.41 billion-$6.49 billion. Separately, BofA Securities raised its price target to $157 from $153.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments